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Objective: To investigate the association between the frequency and intensity of fasciculations 51 
with clinical measures of disease progression in amyotrophic lateral sclerosis (ALS). 52 
Methods: Twenty-four consecutive patients with ALS underwent clinical review and 53 
neuromuscular ultrasound assessment to detect intensity of fasciculations. Results were 54 
correlated with clinical markers of disease severity, as measured by the ALS Functional Rating 55 
Scale-revised (ALSFRS-R) and rate of disease progression (ΔFS), in addition to assessment of 56 
cortical motor function.  57 
Results: Disease duration negatively correlated (R = -0.530, p < 0.01) with fasciculation 58 
intensity, while the ΔFS positively correlated with the fasciculation number (R = 0.626, p < 59 
0.01). In terms of potential central contributions to ectopic impulse generation, patients were 60 
classified into cohorts based on their fasciculation intensity and short interval intracortical 61 
inhibition (SICI). ΔFS was significantly higher in patients with established hyperexcitability 62 
(low SICI) with high fasciculation intensity compared to those patients with minimal SICI 63 
change. 64 
Conclusions: Fasciculation intensity appears linked to disease progression and separately to 65 
markers of cortical dysfunction, specifically the advent of cortical hyperexcitability.  66 
Significance: Assessment of the intensity of patient fasciculations is a noninvasive approach that 67 
may provide further insight disease pathophysiology in ALS. 68 
 69 
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AH, abductor hallucis; ALS, amyotrophic lateral sclerosis; ALSFRS-R, the revised ALS 75 
Functional Rating Scale; APB, abductor pollicis brevis; BB, biceps brachii; FCU, flexor carpi 76 
ulnaris; GC, gastrocnemius; MEP, motor evoked potential; MUS, muscle ultrasound; PS, 10th 77 
cervical paraspinal muscle; RMT, Resting motor threshold; TA, tibialis anterior; TPZ, trapezius; 78 
TMS, transcranial magnetic stimulation; TTTMS, Paired-pulse Threshold tracking TMS; SICI, 79 
short interval intracortical inhibition; UMNS, upper motor neuron clinical score; VL, vastus 80 
lateralis. 81 
  82 
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1. Introduction 83 
   Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease that causes progressive 84 
degeneration of upper and lower motor neurons, with resultant muscle weakness and paralysis. 85 
Fasciculations are considered an early harbinger of ALS and form an important part of various 86 
criteria linked to clinical diagnosis (de Carvalho et al., 2017). Despite being a cornerstone of 87 
clinical diagnosis, knowledge about implications of the intensity of fasciculations in ALS has 88 
not yet been established.    89 
   In terms of definition, fasciculations may best be considered as brief, apparently random and 90 
spontaneous contractions of muscle fibers, and remain a characteristic finding of patients 91 
diagnosed with ALS. Since the establishment of the Awaji criteria, the detection of 92 
fasciculations have been established as an important neurophysiological feature for the 93 
diagnosis of ALS (Hardiman et al., 2011; Kiernan et al., 2011; Turner et al., 2013). Although 94 
the presence of fasciculations in ALS has traditionally been confirmed by electromyography, 95 
neuromuscular ultrasonography has emerged over more recent years as a sensitive, non-invasive 96 
method to detect fasciculations (Walker et al., 1990; Arts et al., 2012; Misawa et al., 2011; 97 
Noto et al., 2018; Noto et al., 2017b).  98 
In terms of their origin, studies to date have suggested that fasciculations may arise 99 
from proximal and distal segments of the peripheral nerve, or alternatively from within the 100 
motor neuron itself. Fasciculations may also arise or be triggered by central processes, linked to 101 
the development of cortical hyperexcitability in ALS (de Carvalho et al, 2017). If accepted that 102 
fasciculations may be driven by the advent of hyperexcitability, such ectopic impulse generation 103 
may arise peripherally (linked to membrane instability of motor axons) or alternatively from a 104 
hyperexcitable corticospinal system, or from both compartments. 105 
   Regardless, the presence of fasciculations can typically be described from a diagnostic 106 
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perspective as being ‘present’ or ‘absent’ , based for instance on the detection of two or more 107 
twitches in a muscle using neuromuscular ultrasound. However, because of the ability of 108 
ultrasound to observe a large muscle surface area, different types of fasciculations have been 109 
detected, defined as intermittent or continuous twitching. Separately, although ultrasound may 110 
seem useful for confirming the presence of fasciculation, it cannot determine the origin or 111 
generator of the neural activity linked to the manifestation of fasciculation. As such, the aim of 112 
the present study was to utilize ultrasound to confirm the presence and intensity of fasciculation 113 
across a range of affected muscles, innervated by different levels of the neural axis. Furthermore, 114 
the present study investigated the correlation between fasciculation intensity and disease 115 
progression, linked to a multimodal approach incorporating markers of peripheral and cortical 116 
function and specifically, the presence of cortical hyperexcitability as identified with 117 
transcranial magnetic stimulation (TMS). 118 
 119 
2. Material and Methods 120 
2.1 Subjects 121 
   In this prospective study, 24 consecutive patients who were referred to the Forefront 122 
Multidisciplinary ALS Clinic (NHMRC Sydney Health Partners Academic Healthcare and 123 
Translation Centre) were recruited. This study was approved by the Human Research Ethics 124 
Committee of the University of Sydney, and all participants gave written informed consent prior 125 
to the study. This study has been carried out in accordance with The Code of Ethics of the World 126 
Medical Association (declaration of Helsinki) 127 
   Patients underwent a comprehensive clinical assessment with subsequent investigation 128 
including ultrasound, neurophysiological assessment, including nerve conduction studies, 129 
electromyography, and central studies of corticomotoneuronal function using threshold tracking 130 
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TMS (TT-TMS). Muscles examined with needle EMG were selected based on the symptom 131 
profile for each patient, in order to confirm whether the clinical presentation fulfilled a 132 
diagnosis of ALS based on available criteria. Patients fulfilled criteria for a diagnosis of 133 
probable or definite ALS according to Awaji criteria (de Carvalho et al., 2008), and 134 
investigations excluded mimic disorders such as multifocal motor neuropathy and spinobulbar 135 
muscular atrophy.  136 
To better determine disease severity and progression, patients were assessed using the 137 
revised ALS Functional Rating Scale (ALSFRS-R) (Cedarbaum et al., 1999). Disease duration 138 
(months) was defined as time between first symptom onset to the visit date, with the rate of 139 
disease progression (ΔFS) calculated as follows: 140 
ΔFS = 48 – (Total ALSFRS-R at initial visit) / Symptom duration (months) (Labra et 141 
al., 2016).  142 
   An upper motor neuron clinical score (UMNS) was utilized to classify patients, determined 143 
by the presence of pathologically brisk reflexes (biceps, supinator, triceps, finger, knee, ankle, 144 
extensor plantar responses assessed bilaterally, and brisk facial and jaw jerks; maximum 145 
possible score = 16) (Turner et al., 2004). Patients with an UMN score of >13 were classified 146 
into an upper motor neuron predominant group. Separately, patients were classified into 147 
phenotypes according to the initial region of clinical involvement (bulbar, upper, or lower limb 148 
onset).  149 
 150 
2.2 Neuromuscular ultrasound 151 
   Ultrasound was performed by a neurologist (JT) with five years of experience in 152 
neuromuscular ultrasound, and who was blinded to the clinical history and neurological 153 
examination findings. Studies were performed using the MyLabTM Alpha ultrasound machine 154 
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(Esoate, Genova, Italy) with a 9-22 MHz broadband linear array transducer (SL2325). Patients 155 
were tested in the supine position with their arms and legs extended and with their muscles 156 
completely relaxed (Arts et al., 2010). Each muscle was scanned transversely using B-mode 157 
with standard transducer locations corresponding to muscle bellies (Misawa et al.,2011). Initial 158 
settings were kept constant for all examinations except depth, which was adjusted depending on 159 
the individual variations such as thickness of their subcutaneous fat. Ultrasound was undertaken 160 
on the following muscles bilaterally: the trapezius (TPZ), biceps brachii (BB), flexor carpi 161 
ulnaris (FCU), abductor pollicis brevis (APB), abductor digiti minimi, 10th thoracic paraspinal 162 
(PS), vastus lateralis (VL), tibialis anterior (TA), gastrocnemius (GC), and abductor hallucis 163 
(AH) muscles, and the tongue (genioglossus muscle). To avoid any impact of exercise of 164 
fasciculation intensity, all patients confirmed the absence of vigorous exercise in the days prior 165 
to evaluation of fasciculations. Each muscle was recorded as following sequential order; tongue, 166 
right upper limb, left upper limb, right lower limb, left lower limb and 10th thoracic paraspinal. 167 
The protocol remained uniform for all patients. Recordings for each muscle were maintained for 168 
a period of at least 60 seconds to accurately determine the presence of fasciculation (Noto et al., 169 
2017a) and were stored as video records. In total, 20 videos per subject were obtained. The 170 
presence of fasciculation was defined as two or more involuntary twitches per muscle (Walker 171 
et al., 1990). In some cases it may seem difficult to determine whether muscle activity reflects 172 
spontaneous fasciculation or alternatively, motor unit activity under voluntary control. In these 173 
instances, voluntary activity may become more evident when patients better understood their 174 
ability to relax their limbs during evaluation. Fasciculation intensity was calculated as the 175 
number of fasciculations over a 60 second period (video 1). Based on recent observations of 176 
fasciculation intensity (Noto et al., 2017a), ultrasound was recorded for 60 seconds, with 177 
fasciculation numbers subsequently counted using a 13.3-inch display screen, visualised in a 178 
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darkened room. For each patient, a sum fasciculation score was calculated for each muscle as 179 
follows: the summed tongue and TPZ muscle fasciculation score (cranial region score), upper 180 
limb sum score, lower limb sum score, and total sum score of all muscles altogether (overall 181 
muscle fasciculation score). These values were also summed to produce an overall fasciculation 182 
sum score. Clinical evaluation, ultrasound and video-recording were undertaken by a single 183 
neurologist (JT). 184 
2.3 Assessment of the central nervous system 185 
   Cortical function was assessed using TT-TMS, conducted using a 90-mm circular coil (for 186 
upper limbs) and 110-mm double cone coil (for lower limbs) applied to the motor cortex, using 187 
two magnetic stimulators connected via a BiStim 2002 system (Magstim Co., Whitland, South 188 
West Wales, UK). The resultant motor evoked potential (MEP) responses were recorded over 189 
the APB muscles bilaterally. The APB muscle was used for recording responses to TMS to 190 
provide a general measure of cortical function, while in contrast, fasciculation intensity was 191 
assessed across a broad range of upper and lower limb muscles. The threshold tracking method 192 
was used as previously reported (Vucic et al., 2006a), with resting motor threthold (RMT) was 193 
defined as the stimulus intensity required to generate a fixed MEP – response of 0.2 mV, when 194 
preceded by a subthreshold conditioning stimulus of 70% RMT were tracked.  195 
   Short interval intracortical inhibition (SICI) was measured at increasing interstimulus 196 
intervals (ISIs; 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, and 7 ms), with stimuli delivered until two consecutive 197 
target MEPs were detected. SICI was calculated using the following equation (Vucic et al., 198 
2006b): 199 
SICI = (Conditioned test stimulus intensity – RMT) / RMT × 100 200 
As in previous studies, the averaged SICI response (ISIs 1-7 ms) was used for analysis of 201 
cortical function.  202 
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  203 
2.4 Statistical analysis 204 
   SPSS version 22 (SPSS Corporation Chicago, USA) was used for all statistical analyses. For 205 
each muscle, correlations were sought between fasciculation intensity and clinical parameters 206 
(disease duration, ALSFRS-R score, and ΔFS) using Spearman’s rank correlation coefficient. 207 
Fasciculation intensity was confirmed between upper motor dominant and lower motor 208 
dominant groups using an unpaired t-test and between ALS subgroups (bulbar onset, upper limb 209 
onset, and lower limb onset) using a one-way ANOVA. Tukey’s range test was used to compare 210 
the fasciculation detection rate between these three subgroups. The association between the 211 
intensity of fasciculations and average SICI were analyzed using Spearman’s rank correlation 212 
coefficient. An unpaired t-test was used to confirm difference of combined subgroup which was 213 
classified into two group based on fasciculation intensity and averaged SICI value. Statistical 214 
significance was considered as p < 0.05.  215 
 216 
3. Results 217 
3.1 Subject characteristics  218 
  In total, 24 patients were recruited, with the patients forming a representative ALS cohort 219 
(Table 1). No patient had a family history of ALS. From this cohort, 58% of patients were 220 
diagnosed with definite ALS and 42% with probable ALS according to the Awaji criteria. 221 
Approximately 21% of patients were bulbar-onset, 33% upper limb and 46% lower limb onset. 222 
In terms of predominant influence evident on clinical assessment, 37.5% were classified as 223 
upper motor neuron dominant, while 62.5% were lower motor neuron dominant.  224 
 225 
3.2 Fasciculation detection 226 
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   Ultrasound evaluation of fasciculations was performed across a total of 480 muscles (all 227 
patients), with more than 25,000 seconds of video recording utilized for reviewing the 228 
fasciculation count for each tested muscle. Overall, fasciculations were observed in more than 229 
half of the tested muscles (56.3%; 270/480 muscles; Figure 1). Compared to the overall 230 
detection rate of fasciculation (56.3%), the biceps brachii had the highest fasciculation detection 231 
rate (75%; p < 0.05), and the paraspinal muscles had the lowest fasciculation detection rate 232 
(29.2%; p < 0.05). Across the total sample, the mean fasciculation number was 13.0 ± 12.9 233 
(mean ± SD) (Table 2). Separately, abductor hallucis had the lowest number of fasciculations 234 
(6.8 ± 7.0, p < 0.01) of all fasciculation-positive muscles.  235 
 236 
3.3 Correlation of fasciculations with clinical parameters 237 
   Clinical parameters (disease duration, ALSFRS-R score, and ΔFS) were correlated with the 238 
presence of fasciculations for each muscle. Disease duration negatively correlated with 239 
fasciculation intensity for both the total sum (R = -0.530, p < 0.01) and lower limb sum scores 240 
(R = -0.632, p < 0.01). The ΔFS positively correlated with fasciculation intensity in total sum (R 241 
= 0.626, p < 0.01; Figure 2.) and in specific tested muscles [Upper limb sum: R=0.504 (p<0.05), 242 
Lower limb sum: R=0.523 (p<0.01), Lt FCU: R=0.482 (p<0.05), Lt TA: R=0.551 (p<0.01), Lt 243 
Gastro: R=0.411 (p<0.05)]. No correlation was observed between fasciculation frequency and 244 
ALSFRS-R score. 245 
  In terms of clinical phenotype, the fasciculation detection rate was similar across all 246 
subgroups, with a rate of 57.0% in the bulbar-onset group, 65.6% in the upper limb-onset group, 247 
and 50.9% in the lower limb-onset group (p=0.385). There were no significant differences 248 
between the upper and lower motor neuron dominant groups in regards to the fasciculation 249 




3.4 Fasciculation intensity and cortical function 252 
   Assessment of central function established a reduction in averaged SICI (ISI 1-7 ms, %), 253 
consistent with cortical hyperexcitability [right-APB 7.1 ± 5.8 (normal value; 10.9±0.8, p<0.05), 254 
left-APB 3.3 ± 4.7 (normal value; 10.9±0.8, p<0.0001)] (Shibuya et al., 2016a). To evaluate the 255 
association between fasciculation intensity and cortical function, intensity was correlated with 256 
averaged SICI values. There was no correlation between the intensity of fasciculation for each 257 
of the total sum scores and SICI [right-APB; R=0.213 (p=0.464), left-APB; R=0.350 258 
(p=0.184)].  259 
   In combined subgroup analysis, patients were classified into two groups based on 260 
fasciculation intensity and SICI data. Specifically, the difference of ΔFS between low SICI with 261 
high fasciculation intensity group was compared to the remaining cohort to determine whether 262 
ΔFS could be influenced by changes in cortical hyperexcitability combined with high 263 
fasciculation intensity. In the patient subgroup with prominent cortical hyperexcitability 264 
(defined as an average SICI of <5.5%) with a high number of fasciculations (defined as more 265 
than 150 fasciculations in total), the ΔFS was significantly higher than for the remaining ALS 266 
patients (low SICI and high fasciculations: 0.93 ± 0.28; remaining ALS patients 0.45 ± 0.35, p < 267 
0.05).  268 
 269 
4. Discussion 270 
   In this cross-sectional clinical, ultrasound and neurophysiological study, the association 271 
between fasciculation intensity was considered relative to clinical parameters, particularly 272 
disease duration and the rate of disease progression in ALS. Analysis of fasciculations as 273 
determined by neuromuscular ultrasound determined that ΔFS positively correlated with the 274 
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intensity of fasciculation and that the combination of cortical hyperexcitability and high 275 
fasciculation intensity combined to promote faster disease progression in ALS. 276 
 277 
4.1 Fasciculation rate 278 
   Overall, fasciculations were observed in more than half of the muscles tested, with the 279 
greatest detection rate identified in the biceps brachii, consistent with previous studies 280 
(Takamatsu et al., 2016; Tsuji et al., 2017). In contrast, abductor hallucis showed the lowest 281 
number of fasciculations in all fasciculation-positive muscles, as well as a low fasciculation 282 
detection rate. The present series suggests that bigger muscles (such as BB and VL) tended to 283 
have higher fasciculation intensity than those of smaller muscles (AH) [BB vs AH; 18.6±17.5 vs 284 
6.8±7.0 p<0.0001, VL vs AH; 15.6±13.9 vs 6.8±7.0 p<0.0001:Unpaired t test]. Of further 285 
interest, the present study has revealed that fasciculation intensity was lowest in AH in the 286 
cohort of ALS patients. In contrast, fasciculations are most common in AH in healthy subjects 287 
(Mitsikistas et al., 1998; Van et al., 1994; Fermont et al., 2010). This observation may have 288 
some clinical relevance, in that it makes isolated fasciculations involving AH appear particularly 289 
benign.  290 
   Separately, disease duration negatively correlated with the fasciculation intensity identified 291 
by ultrasound. Such a finding is consistent with the concept that fasciculations are more 292 
common during the early disease stages and typically become less prominent as the functional 293 
impairment increases, associated with the loss of motor units (Fermont et al., 2010; de 294 
Carvalho and Swash., 2016a). The present study also identified a positive correlation between 295 
the ΔFS and the intensity of fasciculations as determined by neuromuscular ultrasound, 296 
highlighting the utility of ultrasound to serve as a potential marker of disease progression.  297 
   Perhaps surprisingly, there was no difference in fasciculation intensity across ALS 298 
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phenotypes when assessed by site of onset. In addition, there was no difference between patients 299 
with high UMN scores compared to lower UMN scores. Before commencing this study, it may 300 
have been considered more likely that lower UMN score patients would manifest more frequent 301 
fasciculation, if considered that fasciculations were primarily generated by increased lower 302 
motor neuron excitability (de Carvalho and Swash., 2016b). While the origin of fasciculations 303 
remains unclear (de Carvalho et al., 2017), in formal diagnostic criteria, fasciculations are 304 
identified by EMG features of neurogenic change and have typically been considered as 305 
evidence for lower motor neuron involvement (de Carvalho et al., 2008). However, it remains 306 
conceivable that fasciculations arise linked to the generation of cortical hyperexcitability in ALS 307 
(de Carvalho et al., 2017). Furthermore, fasciculations may develop linked to both upper and 308 
motor neuronal impairment, a concept supported by findings from the present study.  309 
 310 
4.2 Central and peripheral function 311 
   Although the exact mechanisms and timing of underlying motor neuron death in ALS 312 
remain unclear, cortical hyperexcitability has been proposed as a contributory mechanism 313 
(Brujin et al., 1997; Trotti et al., 1999). Cortical hyperexcitability, specifically a reduction in 314 
averaged SICI, seems to be the most robust biomarker for ALS and may provide prognostic 315 
insight (Shibuya et al., 2016b; Menon et al., 2015; Simon et al., 2014; Shibuya et al., 2017). 316 
In the present series, ALS patients with evidence of cortical hyperexcitability who also 317 
demonstrated a high fasciculation intensity experienced the fastest clinical decline. Such 318 
findings suggest that this multimodal combination of malignant factors may promote disease 319 
progression in ALS.  320 
  In terms of potential limitations, it is accepted that the fasciculation intensity may be 321 
underestimated in muscles with very frequent fasciculations. To minimize such issues as much 322 
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as possible, whole recordings (more than 25,000 seconds of video recordings) were each 323 
reviewed twice for each muscle before formalizing fasciculation intensity. However, if anything, 324 
underestimating counts may have only served to reduce the strength of the relationships 325 
detected. Separately, it is accepted that the study incorporated a cross-sectional design with data 326 
obtained from a single tertiary centre.  327 
 328 
5. Conclusion 329 
   The present study has established that fasciculation intensity as detected by neuromuscular 330 
ultrasound was associated with disease progression in ALS. Furthermore, the combination of 331 
fasciculation intensity and the advent of cortical hyperexcitability may prove useful for 332 
identifying those patients with more malignant disease and fast progression. Such identification 333 
may be useful in the future stratification of patients in a clinical trial setting. Although, overall 334 
patient numbers were not large in the present series, the studies incorporate ultrasound 335 
observations across 480 muscles and more than 25000 seconds of video recording. Future 336 
studies may explore differences in fasciculation intensity across a range of upper and lower 337 
motor dominant presentations, and amongst ALS subtypes classified by their initial 338 
symptomatology, including familial differences. 339 
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Site of onset 
Bulbar 5 2:3 66.4±5.4 46.2±65.9 43.0±3.8 0.49±0.44 
Upper limb 8 6:2 64.7±12.0 24.5±22.5 38.4±4.3 0.59±0.30 
Lower Limb 11 7:4 55.9±13.4 47.5±88.9 39.5±4.8 0.60±0.50 
ALS (overall)  24 15:9 61.0±12.3 39.6±66.8 39.8±4.6 0.56±0.41 
 446 
 Table 1: Demographic characteristics of study subjects. The site of onset was classified as either 447 
bulbar, upper limb and lower limb onset. The data for age, disease duration, ALSFRS-R and ΔFS are 448 
provided as mean ± standard deviation (SD). ALSFRS-R; revised ALS Functional Rating, ΔFS; the 449 



























The mean number of fasciculation  
in fasciculation detected muscle. 
Brainstem  Tongue 13.6 ± 16.4 
  TPZ 13.2 ± 11.6 
Cervical BB 18.6 ± 17.5 
  FCU 12.37 ± 9.3 
  APB 11.5 ± 15.3 
  ADM 9.8 ± 12.1 
Thoracic PS 7.3 ± 6.6 
Lumbosacral VL 15.6 ± 13.9 
  TA 12.6 ± 12.0 
  GC 13.3 ± 11.8 
  AH 6.8 ± 7.0 ** 
 Overall  13.0±12.9 
 474 
Table 2: Mean fasciculation number of each muscle (mean ±SD). Of the 276 muscles the mean 475 
fasciculation number was 13.0 ± 12.9. AH had the lowest fasciculation number (6.8 ± 7.0, p< 476 











Supplemental data (video 1): ultrasound at vastus lateralis. There can be seen muscle 486 
fasciculations at center slightly left part. (4 fasciculations are counted within recording) 487 
Some pulse artifacts are detected over on the right in this video. 488 
 489 
Highlights 490 
• Fasciculation intensity in patients with amyotrophic lateral sclerosis (ALS) was 491 
measured using neuromuscular ultrasound. 492 
• Fasciculation frequency appears linked to disease progression. 493 
• Assessment of fasciculations is a noninvasive approach that may provide insight into 494 


















Figure 1: The fasciculation detection rate (%) using ultrasound in each muscle. Overall, 511 
muscle fasciculations were observed in more than half of the tested muscles (56.3%; 512 
270/480 muscles). Compared to the overall detection rate of fasciculation the BB had the 513 
highest fasciculation detection rate (75%; p < 0.05), and the PS muscle had the lowest 514 













  526 
 527 
Figure 2: Correlation between fasciculation intensity of total sum score and Δ FS. The ΔFS 528 
was positively correlated with the fasciculation number in total sum (R = 0.626, p < 0.01). 529 
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